Checkpoint Inhibitors in Melanoma Patients with Underlying Autoimmune Disease

References

• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723. doi:10.1056/NEJMoa100346620525992
   PubMed Web of Science ®Google Scholar
• Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers. 2020;12(3):738. doi:10.3390/cancers12030738
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Chiarion‐Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345‐1356. doi:10.1056/NEJMoa1709684
   Web of Science ®Google Scholar
• Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomized, controlled, Phase 2 trial. Lancet Oncol. 2015;16(8):908–918. doi:10.1016/S1470-2045(15)00083-226115796
   PubMed Web of Science ®Google Scholar
• Hamid O, Robert C, Daud A, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019;30:582–588. doi:10.1093/annonc/mdz01130715153
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;318(16):1535–1546. doi:10.1056/NEJMoa1910836
   Web of Science ®Google Scholar
• Wolchok JD, Weber JS, Maio M, et al. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in Phase II clinical trials. Ann Oncol. 2013;24(8):2174–2180. doi:10.1093/annonc/mdt16123666915
   PubMed Web of Science ®Google Scholar
• Haslam A, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Net Open. 2019;2(5):e192535. doi:10.1001/jamanetworkopen.2019.2535
   PubMed Web of Science ®Google Scholar
• Postow MA, Sidlow R, Hellmann MD. Immune‐related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158‐ 168. doi:10.1056/NEJMra1703481
   Web of Science ®Google Scholar
• Wang Y, Zhou S, Yang F, et al. Treatment‐related adverse events of PD‐1 and PD‐L1 inhibitors in clinical trials: a systematic review and meta‐analysis. JAMA Oncol. 2019;5(7):1008‐1019.
   Web of Science ®Google Scholar
• Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta‐analysis. JAMA Oncol. 2018;4(12):1721‐1728. doi:10.1001/jamaoncol.2018.3923
   Web of Science ®Google Scholar
• Kennedy LC, Bhatia S, Thompson JA, Grivas P. Preexisting autoimmune disease: implications for immune checkpoint inhibitor therapy in solid tumors. J Natl Compr Cancer Net. 2019;17(6):750–757. doi:10.6004/jnccn.2019.7310
   PubMed Web of Science ®Google Scholar
• Pantuck M, McDermott D, Drakaki A. To treat or not to treat: patient exclusion in immune oncology clinical trials due to preexisting autoimmune disease. Cancer. 2019;125:3506–3513. doi:10.1002/cncr.3232631318445
   PubMed Web of Science ®Google Scholar
• Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995;3(5):541–547. doi:10.1016/1074-7613(95)90125-67584144
   PubMed Web of Science ®Google Scholar
• Nishimura H, Nose M, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11(2):141–151. doi:10.1016/S1074-7613(00)80089-810485649
   PubMed Web of Science ®Google Scholar
• Nishimura H, Okazaki T, Tanaka Y, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001;291:319–322. doi:10.1126/science.291.5502.31911209085
   PubMed Web of Science ®Google Scholar
• Ueda H, Howson JMM, Esposito L, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature. 2003;423(6939):506–511. doi:10.1038/nature0162112724780
   PubMed Web of Science ®Google Scholar
• Zamani MR, Aslani S, Salmaninejad A, Javan MR, Reaei N. PD-1/PD-L and autoimmunity: a growing relationship. Cell Immunol. 2016;310:27–41. doi:10.1016/j.cellimm.2016.09.00927660198
   PubMed Web of Science ®Google Scholar
• Fang M, Huang W, Mo D, Zhao W, Huang R. Association of five Snps in cytotoxic T-lymphocyte antigen 4 and cancer susceptibility: evidence from 67 studies. Cell Physiol Biochem. 2918;47(1):414–427. doi:10.1159/000489953
   PubMedGoogle Scholar
• Li J, Wang W, Sun Y, Zhu Y. CTLA-4 polymorphisms and predisposition to digestive system malignancies: a meta-analysis of 31 published studies. World J Surg Oncol. 2020;18(1):55. doi:10.1186/s12957-020-1806-232178688
   PubMed Web of Science ®Google Scholar
• Nakano E, Takahashi A, Namikawak K, et al. Correlation between cutaneous adverse events and prognosis in patients with melanoma treated with nivolumab: a single institutional retrospective study. J Dermtol. 2020;47(6):622–628. doi:10.1111/1346-8138.15309
   PubMed Web of Science ®Google Scholar
• Hua C, Boussemart L, Mateus C, et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol. 2016;152(1):45–51. doi:10.1001/jamadermatol.2015.270726501224
   PubMed Web of Science ®Google Scholar
• Teulings HE, Limpens J, Jansen S, et al. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol. 2015;33(7):773–781. doi:10.1200/JCO.2014.57.475625605840
   PubMed Web of Science ®Google Scholar
• Abu-Sbeih H, Ali FS, Qiao W, et al. Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma. Cancer Immunol Immunother. 2019;68(4):553–561. doi:10.1007/s00262-019-02303-130666357
   PubMed Web of Science ®Google Scholar
• Robert C, Hwu WJ, Hamid O, et al. Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: a landmark analysis in patients with advanced melanoma. Eur J Cancer. 2021;144:182–191. doi:10.1016/j.ejca.2020.11.01033360855
   PubMed Web of Science ®Google Scholar
• Eggermont AMM, Kicinski M, Blank CU, et al. Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2020;6(4):519–527. doi:10.1001/jamaoncol.2019.557031895407
   PubMed Web of Science ®Google Scholar
• Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378:1789. doi:10.1056/NEJMoa180235729658430
   PubMed Web of Science ®Google Scholar
• Weber J, Mandala M, Del, Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824–1835. doi:10.1056/NEJMoa170903028891423
   PubMed Web of Science ®Google Scholar
• Zimmer L, Livingstone E, Hassel JC, et al. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomized, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020;395:1558. doi:10.1016/S0140-6736(20)30417-732416781
   PubMed Web of Science ®Google Scholar
• Kehl KL, Yang S, Awad MM, et al. Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer. Cancer Immunol Immunother. 2019;68:817–926. doi:10.1007/s00262-019-02321-z
   Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23–34. doi:10.1056/NEJMoa150403026027431
   PubMed Web of Science ®Google Scholar
• Bender DA, Heilbroner SP, Wang TJC, et al. Increased rates of immunosuppressive treatment and hospitalization after checkpoint inhibitor therapy in cancer patients with autoimmune disease. J Immunother Cancer. 2020;8:e001627. doi:10.1136/jitc-2020-00162733303578
   PubMed Web of Science ®Google Scholar
• Cortellini A, Buti S, Santini D, et al. Clinical outcomes of patients with advanced cancer and pre-existing autoimmune diseases treated with anti-programmed death-1 immunotherapy: a real-world transverse study. Oncologist. 2019;24:e327–e337. doi:10.1634/theoncologist.2018-061830796151
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab N, Shah M, Lopez-Olivo MA, Suarez-Almazor ME. Use of checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review. Ann Int Med. 2018;168(2):121–131. doi:10.7326/M17-207329297009
   PubMed Web of Science ®Google Scholar
• Leonardi GC, Gainor JF, Alltan M, et al. Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders. J Clin Oncol. 2018;36:1905–1912.29746230
   PubMed Web of Science ®Google Scholar
• Johnson DB, Sullivan RJ, Ott PA, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2016;2(2):234–240. doi:10.1001/jamaoncol.2015.436826633184
   PubMed Web of Science ®Google Scholar
• Kahler KC, Eigentler TK, Gesierich A, et al. Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders. Cancer Immunol Immunother. 2018;67(5):825–834. doi:10.1007/s00262-018-2134-z29487980
   PubMed Web of Science ®Google Scholar
• Menzies AM, Johnson DB, Ramanujam S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2017;28(2):368–376. doi:10.1093/annonc/mdw44327687304
   PubMed Web of Science ®Google Scholar
• Bostwick AD, Salama AK, Hanks BA. Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis. J Immunother Cancer. 2015;3(3):19. doi:10.1186/s40425-015-0064-225992290
   PubMedGoogle Scholar
• Grover S, Ruan AB, Srivoleti P, et al. Safety of immune checkpoint inhibitors in patients with pre-existing inflammatory bowel disease and microscopic colitis. JOP. 2020;16(9):e933–e941.
   Google Scholar
• Abu-Sbeih H, Faleck DM, Riccitui B, et al. Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease. J Clin Oncol. 2020;38(6):576–583. doi:10.1200/JCO.19.0167431800340
   PubMed Web of Science ®Google Scholar
• Uemura M, Trinh VA, Haymaker C, et al. Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn’s disease: a case report. J Hematol Oncol. 2016;9:81. doi:10.1186/s13045-016-0309-727595932
   PubMed Web of Science ®Google Scholar
• Frohne CC, Llano EM, Perkovic A, Cohen RD, Luke JL. Complete response of metastatic melanoma in a patient with Crohn’s disease simultaneously receiving anti-alph4beta7 and anti-PD1 antibodies. J Immunother Cancer. 2019;7(1):1. doi:10.1186/s40425-018-0484-x30612589
   PubMed Web of Science ®Google Scholar
• Mellemkjaer L, Linet MS, Frisch M, et al. Rheumatoid arthritis and cancer risk. Eur J Cancer. 1996;32A(10):1753–1757. doi:10.1016/0959-8049(96)00210-98983286
   PubMed Web of Science ®Google Scholar
• Chen Y-J, Chang Y-T, Wang C-B, et al. The risk of cancer in patients with rheumatoid arthritis. Arthritis Rheum. 2011;63(2):352–358. doi:10.1002/art.3013421279991
   PubMed Web of Science ®Google Scholar
• Klinaki E, Katsoulis M, La Vecchia C, et al. Rheumatoid arthritis and cancer risk results from the Greek European prospective investigation into cancer and nutrition cohort. Eur J Cancer Prev. 2018;27(5):502–506. doi:10.1097/CEJ.000000000000034928379883
   PubMed Web of Science ®Google Scholar
• Leipe J, Christ LA, Arnoldi AP, et al. Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy. RMD Open. 2018;4:e000714.30167328
   PubMed Web of Science ®Google Scholar
• Cappelli LC, Brahmer JR, Forde PM, et al. Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen. Semin Arthritis Rheum. 2018;48(3):553–557. doi:10.1016/j.semarthrit.2018.02.01129573850
   PubMed Web of Science ®Google Scholar
• Braaten TJ, Brahmer JR, Forde PM, et al. Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. Ann Rheum Dis. 2020;79(3):332–338. doi:10.1136/annrheumdis-2019-21610931540935
   PubMed Web of Science ®Google Scholar
• Efuni E, Cytryn S, Boland P, et al. Risk of toxicity after initiating immune checkpoint inhibitor treatment in patients with rheumatoid arthritis. J Clin Rheum. 2020.
   Web of Science ®Google Scholar
• Lee B, Wong A, Kee D, et al. The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma. Ann Oncol. 2016;27:1174–1177. doi:10.1093/annonc/mdw05626861600
   PubMed Web of Science ®Google Scholar
• Kyi C, Carvajal RD, Wolchock JD, Postow MA. Ipilimumab in patients with melanoma and autoimmune disease. J Immunother Cancer. 2014;2:35. doi:10.1186/s40425-014-0035-z25349698
   PubMedGoogle Scholar
• Garcia CR, Jayswal R, Adams V, Anthony LB, Villano JL. Multiple sclerosis outcomes after cancer immunotherapy. Clin Transl Oncol. 2019;21:1336–1342. doi:10.1007/s12094-019-02060-830788836
   PubMed Web of Science ®Google Scholar
• Phadke SD, Ghabour R, Swick BL, Swenson A, Milhem M, Zakharia Y. Pembrolizumab therapy triggering an exacerbation of preexisting autoimmune disease: a report of 2 patient cases. J Invest Med. 2016;4:1–15.
   Google Scholar
• Lau KHV, Kumar A, Yang IH, et al. Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab. Muscle Nerve. 2016;54:157–161. doi:10.1002/mus.2514127065302
   PubMed Web of Science ®Google Scholar
• Hannen J, Ernstoff MS, Wang Y, et al. Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy. Ann Oncol. 2020;31(6):724–744. doi:10.1016/j.annonc.2020.03.28532194150
   PubMed Web of Science ®Google Scholar
• Jia XH, Geng LY, Jiang PP, et al. The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors. J Exp Clin Cancer Res. 2020;39(1):2. doi:10.1186/s13046-020-01749-x31910865
   PubMed Web of Science ®Google Scholar